Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer

Cancer

Volumn 118, Issue 5, 2012, Pages 1202-1211

  Bayraktar, Soley ^a   Hernadez Aya, Leonel F ^a,b   Lei, Xiudong ^a   Meric Bernstam, Funda ^a   Litton, Jennifer K ^a   Hsu, Limin ^a   Hortobagyi, Gabriel N ^a   Gonzalez Angulo, Ana M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

adjuvant chemotherapy; diabetes mellitus; metformin; recurrence; survival; triple receptor negative breast cancer

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; PROGESTERONE RECEPTOR; SULFONYLUREA DERIVATIVE; TAXANE DERIVATIVE;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DISTANT METASTASIS FREE SURVIVAL; DRUG EFFECT; DRUG USE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; NEGRO; OBESITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTMENOPAUSE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SURVIVAL TIME; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MIDDLE AGED; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857372409     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26439     Document Type: Article

References (58)

1. Richardson LC, Pollack LA,. Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol. 2005; 2: 48-53. (Pubitemid 40823181)
2. Frasca F, Pandini G, Sciacca L, et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem. 2008; 114: 23-37. (Pubitemid 351998752)
3. Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE,. Increased prevalence of prior breast cancer in women with newly diagnosed diabetes. Breast Cancer Res Treat. 2006; 98: 303-309. (Pubitemid 44195600)
4. Wolf I, Sadetzki S, Gluck I, et al. Association between diabetes mellitus and adverse characteristics of breast cancer at presentation. Eur J Cancer. 2006; 42: 1077-1082.
5. Hjartaker A, Langseth H, Weiderpass E,. Obesity and diabetes epidemics: cancer repercussions. Adv Exp Med Biol. 2008; 630: 72-93.
6. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD,. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005; 330: 1304-1305. (Pubitemid 40813563)
7. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM,. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009; 32: 1620-1625.
8. Currie CJ, Poole CD, Gale EA,. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009; 52: 1766-1777.
9. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR,. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care. 2010; 33: 1304-1308.
10. Bowker SL, Majumdar SR, Veugelers P, Johnson JA,. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: response to Farooki and Schneider. Diabetes Care. 2006; 29: 1990-1991. (Pubitemid 44156679)
11. Berstein LM,. Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer. Cancer Lett. 2005; 224: 203-212. (Pubitemid 40731528)
12. Hadad SM, Fleming S, Thompson AM,. Targeting AMPK: a new therapeutic opportunity in breast cancer. Crit Rev Oncol Hematol. 2008; 67: 1-7.
13. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N,. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007; 67: 10804-10812. (Pubitemid 350145909)
14. Rice S, Pellatt L, Ramanathan K, Whitehead SA, Mason HD,. Metformin inhibits aromatase via an extracellular signal-regulated kinase-mediated pathway. Endocrinology. 2009; 150: 4794-4801.
15. Berstein LM,. Metformin, insulin, breast cancer and more⋯ Future Oncol. 2009; 5: 309-312.
16. Brown KA, Hunger NI, Docanto M, Simpson ER,. Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. Breast Cancer Res Treat. 2010; 123: 591-596.
17. Alimova IN, Liu B, Fan Z, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle. 2009; 8: 909-915.
18. Liu B, Fan Z, Edgerton SM, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 2009; 8: 2031-2040.
19. Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008; 27: 3576-3586. (Pubitemid 351793803)
20. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual and Handbook. 7th ed. New York: Springer; 2010.
21. The World Health Organization Histological Typing of Breast Tumors-Second Edition. The World Organization. Am J Clin Pathol. 1982; 78: 806-816.
22. Black MM, Speer FD,. Nuclear structure in cancer tissues. Surg Gynecol Obstet. 1957; 105: 97-102.
23. Hess KR, Serachitopol DM, Brown BW,. Hazard function estimators: a simulation study. Stat Med. 1999; 18: 3075-3088. (Pubitemid 29526945)
24. Chlebowski RT, Blackburn GL, Thomson CA, et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst. 2006; 98: 1767-1776. (Pubitemid 46017928)
25. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009; 27: 3297-3302.
26. Galli A, Mello T, Ceni E, Surrenti E, Surrenti C,. The potential of antidiabetic thiazolidinediones for anticancer therapy. Expert Opin Investig Drugs. 2006; 15: 1039-1049. (Pubitemid 44314656)
27. Ararat E, Sahin I, Altundag K,. Aspirin intake may prevent metastasis in patients with triple-negative breast cancer [published online ahead of print July 29, 2010]. Med Oncol.
28. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE,. Aspirin intake and survival after breast cancer. J Clin Oncol. 2010; 28: 1467-1472.
29. Ghosh-Choudhury N, Mandal CC, Ghosh-Choudhury N, Ghosh Choudhury G,. Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth. Cell Signal. 2010; 22: 749-758.
30. Garwood ER, Kumar AS, Baehner FL, et al. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat. 2010; 119: 137-144.
31. Molteni A, Heffelfinger S, Moulder JE, Uhal B, Castellani WJ,. Potential deployment of angiotensin I converting enzyme inhibitors and of angiotensin II type 1 and type 2 receptor blockers in cancer chemotherapy. Anticancer Agents Med Chem. 2006; 6: 451-460. (Pubitemid 44377779)
32. Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW,. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA. 2001; 285: 885-892. (Pubitemid 32171549)
33. Verlato G, Zoppini G, Bonora E, Muggeo M,. Mortality from site-specific malignancies in type 2 diabetic patients from Verona. Diabetes Care. 2003; 26: 1047-1051. (Pubitemid 36929246)
34. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ,. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004; 159: 1160-1167. (Pubitemid 38747263)
35. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295: 2492-2502. (Pubitemid 43854964)
36. Woodward WA, Huang EH, McNeese MD, et al. African-American race is associated with a poorer overall survival rate for breast cancer patients treated with mastectomy and doxorubicin-based chemotherapy. Cancer. 2006; 107: 2662-2668. (Pubitemid 44845622)
37. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M,. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008; 371: 569-578. (Pubitemid 351232031)
38. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ,. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348: 1625-1638. (Pubitemid 36459468)
39. Fleming ST, Rastogi A, Dmitrienko A, Johnson KD,. A comprehensive prognostic index to predict survival based on multiple comorbidities: a focus on breast cancer. Med Care. 1999; 37: 601-614.
40. Baserga R, Peruzzi F, Reiss K,. The IGF-1 receptor in cancer biology. Int J Cancer. 2003; 107: 873-877. (Pubitemid 37429826)
41. Lopez T, Hanahan D,. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell. 2002; 1: 339-353. (Pubitemid 41039136)
42. Jones RA, Campbell CI, Gunther EJ, et al. Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene. 2007; 26: 1636-1644. (Pubitemid 46398739)
43. Gonzalez-Angulo AM, Meric-Bernstam F,. Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res. 2010; 16: 1695-1700.
44. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001; 108: 1167-1174. (Pubitemid 32995375)
45. Towler MC, Hardie DG,. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res. 2007; 100: 328-341.
46. Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M, Fantus IG,. Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer. 2008; 8: 501-505.
47. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ,. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care. 2010; 33: 322-326.
48. Goodwin PJ, Pritchard KI, Ennis M, et al. Metformin lowers fasting insulin levels in nondiabetic hyperinsulinemic early stage breast cancer patients. Breast Cancer Res Treat. 2006 (Suppl 1); 100: 109 Abst 2085.
49. Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol. 2002; 20: 42-51. (Pubitemid 34032594)
50. Pollak MN, Chapman JW, Shepherd L, et al. Insulin resistance, estimated by serum C-peptide level, is associated with reduced event-free survival for postmenopausal women in NCIC CTG MA. 14 adjuvant breast cancer trial. J Clin Oncol. 2006 ASCO Annual Meeting Proceedings Part 1; 24 (June 20 Suppl): 524.
51. Chlebowski RT, Blackburn GL, Hoy MK, et al. Survival analyses from the Women's Intervention Nutrition Study (WINS) evaluating dietary fat reduction and breast cancer outcome. J Clin Oncol. 2008; 26 (12 suppl):26 (May 20 Suppl): Abst 522.
52. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006; 19: 264-271. (Pubitemid 43117611)
53. Rodriguez-Pinilla SM, Sarrio D, Honrado E, et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res. 2006; 12: 1533-1539.
54. Dawood S, Broglio K, Kau SW, et al. Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol. 2009; 27: 220-226.
55. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA,. Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status. Cancer. 2009; 115: 4917-4923.
56. Solin LJ, Hwang WT, Vapiwala N,. Outcome after breast conservation treatment with radiation for women with triple-negative early-stage invasive breast carcinoma. Clin Breast Cancer. 2009; 9: 96-100.
57. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008; 14: 1368-1376. (Pubitemid 351413917)
58. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K,. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009; 69: 7507-7511.